Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 2/20 | 0.55 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.71 |
| ▸ | APEX1 | P27695 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642130 | 0.97 | PARP10 (0.74) | PARP10APEX1F2PRSS1PRSS3 | |
| Terephthalamide SCHEMBL437011 | 0.97 | PARP10 (0.74) | PARP10APEX1F2PRSS1PRSS3 | |
| SCHEMBL56532 | 0.97 | PARP10 (0.74) | PARP10APEX1F2PRSS1PRSS3 | |
| Water SCHEMBL6343332 | 0.94 | PARP10 (0.71) | PARP10APEX1F2PRSS1PRSS3 | |
| Benzene SCHEMBL6865184 | 0.92 | PARP10 (0.68) | PARP10APEX1F2PRSS1PRSS3 | |
| Benzene SCHEMBL28558933 | 0.92 | PARP10 (0.68) | PARP10APEX1F2PRSS1PRSS3 | |
| SCHEMBL3786517 | 0.90 | PARP10 (0.65) | PARP10PARP1POLBTSHRTDP1 | |
| Benzidine SCHEMBL9460959 | 0.90 | PARP10 (0.65) | PARP10PARP1POLBTSHRTDP1 | |
| SCHEMBL19716260 | 0.90 | PARP10 (0.65) | PARP10APEX1F2PRSS1PRSS3 | |
| Terephthalamide SCHEMBL1087289 | 0.88 | PARP1 (0.67) | PARP10PARP1POLBTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | claimed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | claimed |
| CN-1337950-A | 2-oxoquinoline compounds and medicinal uses thereof | JAPAN TOBACCO INC (JP) | 2002-02-27 | — | — | CN | claimed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6806276-B2 | SIDE EFFECT REDUCTION ON CENTRAL NERVOUS SYSTEM; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | JAPAN TOBACCO INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030232855-A1 | Therapeutic agent for allergic disease | JAPAN TOBACCO INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | disclosed |
| CN-1337950-A | 2-oxoquinoline compounds and medicinal uses thereof | JAPAN TOBACCO INC (JP) | 2002-02-27 | — | — | CN | disclosed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-1992005159-A1 | 2-PHENYL-PYRIMIDINES, PROCESS FOR PRODUCING THE SAME, AGENTS CONTAINING THE SAME AND THEIR USE AS FUNGICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-04-02 | — | — | WO | disclosed |
| US-4258033-A | CORONARY VASODILATORS EFFECTIVE IN ISCHEMIC HEART DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232855-A1 | Therapeutic agent for allergic disease | CNR1, CNR2, HRH4 | PARP1 1498/4885CA2 637/4885PARP10 1333/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | PARP1 4258/4885CA2 1773/4885PARP10 1448/4885 |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | CNR2, CNR1, OPRL1 | PARP1 2163/4885CA2 687/4885PARP10 1971/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | PARP1 3980/4885CA2 1273/4885PARP10 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.